Business Standard

Sun Pharma slips 4% on posting Rs 2,277 crores loss in Q4

The loss came on account of settlement charges of pending litigations in the US, and restructuring operations in some countries. Adjusted profit grew 18 per cent year on year (YoY) to Rs 1,582 crore.

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
Premium

SI Reporter Mumbai
Shares of Sun Pharmaceutical Industries slipped 4 per cent to Rs 851.50 on the BSE in Tuesday’s trade, falling 6 per cent since yesterday when the company posted a net loss of Rs 2,277 crore for the fourth quarter of the financial year 2021-22 (Q4FY22).

The loss came on account of settlement charges of pending litigations in the US, and restructuring operations in some countries. Adjusted profit grew 18 per cent year on year (YoY) to Rs 1,582 crore.

Consolidated sales from operations rose 11 per cent YoY at Rs 9,386 crore over Q4 last year. Earnings before

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in